The SusChem News Blog is now hosted on the SusChem website in the News Room. You will be redirected there in 10 seconds
.

Sunday, 18 September 2011

Warsaw to showcase SusChem FP7 success

When the European Commission’s FP7 Programme was launched in 2007 its aim was to increase productivity and economic growth through innovation. SusChem had already developed its Strategic Research Agenda to promote collaborative Research, Development and Innovation between European industry and academia in the fields of Industrial Biotechnology, Materials Technology and Reaction and Process Design and many of its ideas and concepts were incorporated into the initial calls for FP7. Now these initial FP7 projects are being competed.

To celebrate the successful conclusion of these initial ‘SusChem inspired’ projects, SusChem is organising an event in collaboration with SusChem Poland under the patronage of the Polish Presidency of the EU to share the outcomes of three successful SusChem FP7 projects that all included Polish participants.

The event, which takes place at Warsaw University on 18 October is entitled ‘SusChem’s FP7 Success Stories: Creating economic value through effective collaboration’ and will feature FP7 projects: EUMET, EFECTS and INTENANT.

The projects
EUMET (Design, Development, Utilization and Commercialization Of Olefin Metathesis Catalysts). Led by St Andrews University in the UK, EUMET has developed a range of novel olefin metathesis catalysts which exceed the state of the art. The first example has already been scaled-up by industrial partner Umicore and is available from chemical research catalogues. Improved olefin metathesis catalysts have also been discovered and approved for the synthesis of a Janssen Pharmaceuticals drug currently in Phase III clinical trials.

INTENANT (Integrated synthesis and purification of single enantiomers). Coorodinated by Max Planck Institute, Magdeburg in Germany the project has looked to simplify the synthesis, purification and yields of enantiomeric substances for the pharmaceutical industry. In partnership with AstraZeneca, Bayer Technical Services and Molisa improved process technologies have been developed and applied to the development each of the company’s development pipelines. Training in the application of the methodologies is being rolled-out across the companies and is changing how they perform their candidate drug pipeline development. A spin-out company FGEN has also been formed which uses the technology developed in INTENANT to develop optimized biocatalysts.

EFECTS (Efficient Environmental-Friendly Electro-Ceramics Coating Technology and Synthesis) was coordinated by the University of Ghent in Belgium and has advanced the use of ink-jet printing technology to develop functional electro-ceramic coatings which have been incorporated into commercial products as diverse as high-temperature superconductors for Zenergy Power’s wind turbines and Nanophos’s self-cleaning ceramic tiles.

The SusChem Newsblog will be featuring case studies from further ‘SusChem inspired’ collaborative projects over the next few months.

SusChem – key to chemistry
This event will bring together European policy-makers, politicians, industry and academia to discuss to share the benefits and impacts that have resulted though collaboration in these and other FP7 projects and discuss best practice for maximising commercial impact from collaboration.

In addition speakers from the European Commission will outline the FP7’s successor programme: Horizon 2020. And SusChem representatives, including Prof Rodney Townsend, will describe the vision and strategy that the technology platform will be taking to maximise the benefits of sustainable chemistry for the chemical community, the European Union and its citizens.

More information
For more information on the Warsaw SusChem Success event take a look at the SusChem website. In particular you can find the agenda for the event here and can register directly for the event here.

For further information and specific queries please contact the SusChem secretariat.

No comments:

Post a Comment

Please post your comment here. Please note that this newsblog is not moderated.

Note: only a member of this blog may post a comment.